ETHEL ICOSAPENTATE CAPSULES
Icosapent Ethyl Soft Capsules
Specialized medication for hyperlipidemia and arterial plaque
EPA preparation - Highly purified omega-3 fatty acid from fish oil
Exclusive Distributor:
WUZHOU DRUG INTERNATIONAL TRADING LIMITED
澳门五洲药物国际贸易有限公司
Manufacturer:
Biomedics Co., Ltd.
株式会社ビオメディクス
Product Information
ETHEL ICOSAPENTATE CAPSULES is a high-quality EPA preparation manufactured by Biomedics Co., Ltd., specifically designed for treating hyperlipidemia and improving symptoms associated with obstructive arteriosclerosis.
Basic Information
Generic Name
Icosapent Ethyl
Brand Name
Ethel Icosapentate
Drug Classification
EPA Preparation
Classification Code
2189, 3399
Primary Mechanisms of Action
- Reduces blood triglyceride and cholesterol levels
- Antiplatelet action, preventing blood clot formation
- Maintains vascular elasticity and improves circulation
- Provides anti-inflammatory and antioxidant effects
Indications
Hyperlipidemia
Used for treating elevated blood cholesterol and triglyceride levels. By reducing blood lipid levels, it helps decrease the risk of cardiovascular diseases.
Note: Thorough examination is required before use to confirm the diagnosis of hyperlipidemia before considering this medication.
Obstructive Arteriosclerosis
Improves symptoms associated with obstructive arteriosclerosis including ulcers, pain, and coldness. Promotes blood circulation and alleviates related discomfort.
Symptom Improvement: Ulcer healing, pain relief, improved limb coldness
Dosage and Administration
Strictly follow physician's instructions for medication use; do not adjust dosage independently
Hyperlipidemia
Standard Dosage
Adults: 900mg (3 capsules) twice daily, or 600mg (2 capsules) three times daily, taken immediately after meals
Triglyceride Abnormality
Depending on severity, dosage may be increased up to 900mg (3 capsules) three times daily
Obstructive Arteriosclerosis
Standard Dosage
Adults: 600mg (2 capsules) three times daily, taken immediately after each meal
Individual Adjustment
Dosage may be adjusted appropriately based on age and symptoms
Important Notes
- • Must be used under physician guidance
- • Take immediately after meals to enhance absorption
- • Regular blood tests required to monitor treatment efficacy
- • Combine with dietary therapy and exercise therapy
Safety Information
Please carefully read the following safety information and contraindications before use
Contraindications
- •Patients with bleeding (hemophilia, capillary fragility, gastrointestinal ulcers, urinary bleeding, hemoptysis, vitreous hemorrhage, etc.)
- •Patients currently using mifepristone-misoprostol
Special Precautions
- •Patients with bleeding tendencies require careful use
- •Patients during menstrual periods
- •Patients scheduled for surgery
Special Populations
Pregnant Women
Use only when treatment benefits outweigh risks
Nursing Women
Consider treatment benefits vs. breastfeeding benefits when deciding whether to continue nursing
Pediatric Patients
Safety and efficacy clinical trials have not been conducted in pediatric patients
Clinical Data
Evidence-based medicine supported by large-scale clinical research
Cardiovascular Event Prevention Studies
Large-scale clinical trials have confirmed that icosapent ethyl significantly reduces cardiovascular event risk in patients with hypertriglyceridemia, including heart attacks, strokes, and hospitalization due to unstable angina.
Mechanism of Action Studies
Research shows that EPA reduces atherosclerotic risk by decreasing the number of apolipoprotein B molecules. ApoB molecules play a key role in atherosclerosis formation.
Clinical Efficacy Data
Major cardiovascular event risk reduction
Maximum LDL-C reduction
mmol LDL-years risk threshold
Medical Professionals Message Board
Share your clinical experience and insights
Loading messages...
Contact Us
Please feel free to contact us with any questions
Phone Consultation
+853 6588 5387
Email Contact
info@droga.cn
Product Materials
Professional Support
Medical Consultation Services